Where Industry Meet Trends

ai robot image

Contract development and manufacturing organisation (CDMO) LGM Pharma has announced a significant expansion of its analytical testing services, accompanied by a 50% increase in capacity and a $2 million investment.

This development strengthens its existing offerings and aligns with the introduction of new expertise in suppository manufacturing. The aim is to enhance internal capabilities to facilitate growth and provide customers with simplified and comprehensive manufacturing solutions. With extensive analytical testing capabilities for small-molecule drug substances and products, LGM Pharma caters to a diverse range of clients, including both established pharmaceutical companies and start-ups. This strategic enhancement positions the company to meet the evolving needs of the pharmaceutical industry efficiently and effectively.
Read more from PT

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish